Xuefeng YU, co-founder, Chief Executive Officer(CEO) and Chairman of CanSino Biologics. He is primarily responsible for overseeing strategic development, overall operations and management as well as being the major decision-making force of our company. In addition, Dr. Yu is also responsible for managing our commercial operations center. He has more than 30 years' experience in biotech research and development. From September 1990 to June 1991, Dr. Yu worked as a lecturer in the Biology Department at Nankai University. From 1996 to 1998, he served as staff scientist at IBEX Technologies, Inc. (a company listed on the Toronto Stock Exchange Venture Exchange, ticker symbol: IBT). Dr. Yu joined Sanofi Pasteur in May 1998 and held the position of director of fermentation development in Canada when he left the company in August 2009.
Shou Bai CHAO, Chief Operating Officer(COO) and Executive Director of CanSino Biologics. He is deputy general manager of our company and is primarily responsible for the management of daily operations and strategy development. In addition, Dr. Chao also oversees production management and quality control. With nearly 33 years' experience in the biotechnology industry, he formerly served as Vice President and Senior Vice President at AstraZeneca plc from January 2008 to April 2018, and was president and the Board Director at the Chinese Biopharmaceutical Association-USA from June 2014 to June 2016.
Tao ZHU, co-founder, Chief Scientific Officer(CSO) and Executive Director of CanSino Biologics. He is primarily responsible for leading vaccine research and development for CanSinoBIO. In addition, Dr. Zhu also oversees the management of regulatory and clinical affairs. Together with experts from the Academy of Military Medical Sciences, Dr. Zhu led the development and pre-clinical research of the only available recombinant ebola vaccine in China, the production of which was approved by the CFDA. He also led the combinational vaccine project and PBPV project, both of which have been selected as one of the major science and technology projects in the National Twelfth Five-Year Plan for “Significant New Drug Creation” . His achievements also include the establishment of a conjugation technology platform and the development of a variety of vectors including CRM197, plus the process development, pre-clinical research and clinical application of several products, including MCV4, and the invention of seven patents in the PRC.
Dongxu QIU, co-founder, Executive Vice President and Executive Director of CanSino Biologics.He is primarily responsible for advising on the business and strategic development of our company. Dr. Qiu has around 25 years' experience in the biotechnology industry. Dr. Qiu has led several rounds of corporate financing as well as the technology transfers . From January 1993 to April 1997, he was a research scientist at Biomira. Inc. From 1999 to 2000, he served as associate director of product operations at Altarex Inc., responsible for analytical development and product formulation. Dr. Qiu became head of scientific operations at ARIUS Research Inc. from 2000 to 2002, president of Asia at MDS Capital from May 2003 to September 2005, deputy general manager at Shanghai Jima Pharmaceutical Technology Co., Ltd. from 2006 to 2009, and general manager at ChinaBio LLC from March 2007 to April 2011.
Jing WANG, Executive Director and Chief Commercial Officer of CanSino Biologics, is mainly responsible for the company's overall commercial operation. Ms. Wang holds a bachelor degree in Economics, a master degree in engineering of Peking University and Global EMBA of CEIBS. After joining the Company in June 2012, Ms. Wang has made outstanding achievements in previous positions such as director of personnel,administration department, operation director, financial director and assistant to the chairman. Ms. Wang has led the establishment of our financing, financial operations, human resource and administration systems as well as completing the pre-IPO fundraising of approximately RMB743 million. Ms. Wang successfully led the Company’s IPO on Main Board of Hong Kong Stock Exchange in 2019 and on the Sci-tech Innovation Board of the Shanghai Stock Exchange in August 2020, making the Company the first “A+H” dual listing vaccine company.
Xi LUO joined the company in September 2021. She serves as chief financial officer, responsible for the company's financial management and capital operation, including the construction and management of the group's financial and internal control system, the development of investment and financing platforms and channels, the decision-making of business operation and investment and financing activities, the compliance governance of listed companies, investor relations management, etc. Ms. Luo has nearly 15 years of experience in brokerage research and investment banking, including IPO of small and medium-sized board, IPO of the Science and Technology Innovation Board, IPO of Second-board Market, refinancing of the Science and Technology Innovation Board, M & A and transfer of control of listed companies. Ms. Luo participated in the IPO of CanSinoBIO, making the company the first “A+H” dual listing vaccine company. Before joining the company, Ms. Luo successfully led IPO, refinancing or M&A of Double Medical Technology Inc., Sinocelltech Group Limited, Sino Biological Inc., Joinn Laboratories (China) Co., Ltd., Novogene Co., Ltd., Changchun BCHT Biotechnology Co., Sansure Biotech Inc. Ms. Luo graduated from Peking Union Medical College and majored in microbiological and biochemical pharmarcy.